aftin-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: aftin-5
• 英文别名: Aftin-5；(2R)-2-[[6-(N-methylanilino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol
• 化学式: C₁₉H₂₆N₆O
• 分子量: 354.455
• InChiKey: HYFZLABHJHEEFS-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  79.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-chloro-N-methyl-N-phenyl-7H-purin-6-amine 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 生成 aftin-5
  参考文献：
  名称：

  Purine derivatives as tools for screening anti-Alzheimer compounds

  摘要：

  公开号：

  EP2664619B1

文献信息

• [EN] PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES<br/>[FR] DÉRIVÉS DE PURINE EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT D'UNE LÉSION CÉRÉBRALE HYPOXIQUE-ISCHÉMIQUE NÉONATALE ET DE MALADIES ASSOCIÉES
  申请人：COMMISSARIAT ENERGIE ATOMIQUE

  公开号：WO2021214315A1

  公开（公告）日：2021-10-28

  The present invention relates to a compound of formula (I), for use in the treatment of non-traumatic acquired brain injury, in which M represents a NR1R2 group, an OR1 group or a SR1 group, A represents a NR4R5 group, an OR10 group or a hydrogen atom, R3 is a (C1-C6)alkyl group, a (C1-C6)cycloalkyl group, an aryl group, a -CH2-aryl group, a CH2-(C1-C6)cycloalkyl group or a -CH2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. The present invention further relates to a compound of formula (I) wherein R5 is a (C1-C8)alkyl group or a (C1-C6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three -OCORa group(s).

  本发明涉及一种具有式（I）的化合物，用于治疗非创伤性获得性脑损伤，其中M代表NR1R2基团、OR1基团或SR1基团，A代表NR4R5基团、OR10基团或氢原子，R3是（C1-C6）烷基基团、（C1-C6）环烷基基团、芳基、-CH2-芳基、CH2-(C1-C6)环烷基基团或-CH2-杂芳基，以及其与药学上可接受的酸形成的加合盐。本发明还涉及式（I）中R5为（C1-C8）烷基基团或（C1-C6）环烷基基团的化合物，所述烷基和环烷基基团被一个、两个或三个-OCORa基团取代。
• PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES
  申请人：Commissariat à l'énergie atomique et aux énergies alternatives

  公开号：EP3901154A1

  公开（公告）日：2021-10-27

  The present invention relates to a compound of formula (I), for use in the treatment of non-traumatic acquired brain injury, in which M represents a NR1R2 group, an OR1 group or a SR1 group, A represents a NR4R5 group, an OR10 group or a hydrogen atom, R3 is a (C1-C6)alkyl group, a (C1-C6)cycloalkyl group, an aryl group, a -CH2-aryl group, a CH2-(C1-C6)cycloalkyl group or a -CH2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. The present invention further relates to a compound of formula (I) wherein R5 is a (C1-C8)alkyl group or a (C1-C6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three -OCORa group(s).

  本发明涉及一种用于治疗非创伤性后天性脑损伤的式 (I) 化合物、 其中M代表NR1R2基团、OR1基团或SR1基团，A代表NR4R5基团、OR10基团或氢原子，R3是(C1-C6)烷基、(C1-C6)环烷基、芳基、-CH2-芳基、CH2-(C1-C6)环烷基或-CH2-杂芳基，及其与药学上可接受的酸的加成盐。 本发明进一步涉及式 (I) 的化合物，其中 R5 是 (C1-C8) 烷基或 (C1-C6) 环烷基，所述烷基和环烷基被一个、两个或三个 -OCORa 基团取代。
• Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
  申请人：COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

  公开号：US11472807B2

  公开（公告）日：2022-10-18

  Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.

  式(I)化合物 及其与药学上可接受的酸的加成盐，以及向有需要的人施用有效量的该化合物或其任何药学上可接受的盐的方法（作为药物）。
• PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS
  申请人：COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

  公开号：US20200354364A1

  公开（公告）日：2020-11-12

  Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.
• Purine derivatives as tools for screening anti-Alzheimer compounds
  申请人：Manros Therapeutics

  公开号：EP2664619B1

  公开（公告）日：2017-07-12